Dow inks catalyst agreement with Symyx
Under their latest agreement, Symyx will develop catalysts for pharmaceutical intermediate manufacture. In return for exclusive rights to the catalysts, Dow will fund the research and make payments linked to the technical success and commercialization of the catalysts.
"This is our third agreement with Dow," says Symyx chairman/CEO Steven Goldby. "We now have a relationship with them in each of our three business areas: first in Industry Collaborations, then in Discovery Tools, and now in our Proprietary Materials Effort."
The latest agreement was signed by Dow Contract Manufacturing Services (CMS), a Dow business unit that provides contract chemical manufacturing and process development for the pharmaceutical, biotechnology, agricultural, specialty chemical, and specialty polymer industries.
In addition to more than one dozen of its own integrated manufacturing facilities in North America and Europe, the unit has access to Dow's 123 manufacturing sites in 32 countries around the world.
"Symyx has been an important partner for Dow in the area of materials discovery," says Dow Contract Manufacturing Services business director Maggi Walker. "We are pleased to expand the application of their catalyst discovery technologies to our pharmaceutical efforts."
By Alan S. Brown
Managing Editor, Chemical Online
abrown@vertical.net